Market Cap: $2.1B
AI
ADMA Biologics, Inc.
ADMA
NASDAQ (NASDAQ Global Market)USD
Market Cap: $2.1B
ADMA Biologics, Inc. ( ADMA ) is currently navigating a challenging landscape marked by multifaceted legal issues and potential growth opportunities. With its flagship product, ASCENIV, recently recei…
ADMA Biologics, Inc. ( ADMA ) is at a critical juncture, grappling with significant legal and financial challenges while also aiming to capitalize on recent regulatory approvals that could reshape its…
ADMA Biologics, Inc. (https://cashumarkets.com/stock/adma) is at a pivotal moment in its history. The biotechnology firm, which specializes in developing and manufacturing human blood plasma-derived p…
ADMA Biologics, Inc. (https://cashumarkets.com/stock/adma) has recently found itself embroiled in significant legal challenges that threaten its financial stability and investor confidence. Following…
ADMA Biologics is facing serious legal challenges as multiple law firms file class action lawsuits citing significant allegations against the company. The lawsuits accuse ADMA Biologics of engaging in…
Adma Biologics (Ticker: ADMA) achieves a significant milestone with its recent approval from the FDA to expand the label for its product ASCENIV. This newly approved indication allows the use of ASCEN…
Concerns Arise Over ADMA Biologics' Financial Practices Amid Investigations ADMA Biologics, Inc. is currently facing scrutiny over its financial practices following a report by short seller Culper Res…
Allegations of Financial Misconduct Cast a Shadow on ADMA Biologics A recent report from Culper Research has raised troubling allegations against ADMA Biologics, suggesting serious misrepresentations…
ADMA Biologics Marks Significant Growth in Q4 Earnings Report ADMA Biologics, a biopharmaceutical company specializing in the development and commercialization of therapeutic products for the treatmen…
ADMA Biologics Shows Strong Growth in Q4 Earnings Report On February 25, 2026, ADMA Biologics (NASDAQ:ADMA) reveals impressive results for its fourth-quarter earnings, showcasing the company’s robust…
ADMA Biologics Sees Shift in Investor Sentiment Amid Decreased Short Interest ADMA Biologics Inc., a biopharmaceutical company specializing in the development and commercialization of human plasma and…
Adma Biologics Sees Shift in Market Sentiment with Reduced Short Interest ADMA Biologics Inc. reports a notable decrease in its short interest, with a 4.98% decline since the last update. The current…
ADMA Biologics Prepares for Earnings Season Amidst Industry Growth In the biopharmaceutical sector, ADMA Biologics emerges as a key player as the company gears up for its upcoming earnings report. Thi…
Adma Biologics: Pioneering Growth in the Biopharmaceutical Sector Adma Biologics, a prominent player in the biopharmaceutical industry, continues to solidify its market position through strategic init…
Adma Biologics Advances in Immunotherapy Development Adma Biologics, a company specializing in the development of immunoglobulin products and therapies for patients with immune deficiencies, is making…
Adma Biologics Enhances Focus on Immunoglobulin Therapy Amid Market Optimism In a landscape where the biopharmaceutical sector is increasingly pivotal, Adma Biologics concentrates on its core mission…
Adma Biologics Advances in Immunotherapy Solutions Adma Biologics, a leader in the development and commercialization of specialty biologics, continues to push the boundaries of immunotherapy solutions…
ADMA Biologics Sees Positive Shift in Trader Sentiment Amid Decrease in Short Interest ADMA Biologics experiences a significant shift in trader sentiment as it reports a notable decline in short inter…
ADMA Biologics Experiences Positive Shift in Trader Sentiment ADMA Biologics, a biopharmaceutical company specializing in the development and commercialization of immune globulin products, is witnessi…
ADMA Biologics Sees Shift in Short Interest Dynamics ADMA Biologics, a company focused on developing and commercializing specialty biologics, experiences a notable decrease in its short interest, with…
ADMA Biologics Faces Notable Shift in Market Sentiment ADMA Biologics, a biotechnology firm specializing in the development and commercialization of human immunoglobulin products, experiences a notabl…
Adma Biologics Faces Decreasing Short Interest, Signaling Potential Market Confidence ADMA Biologics, a company specializing in the development and commercialization of innovative biologic products, c…
Adma Biologics Faces Growing Bearish Sentiment Amid Rising Short Interest ADMA Biologics, a company in the biopharmaceutical sector specializing in the development and commercialization of immunoglobu…
ADMA Biologics Faces Increased Short Interest Amid Market Concerns ADMA Biologics, a prominent player in the biopharmaceutical industry, is currently experiencing a significant rise in short interest,…
ADMA Biologics Faces Increased Short Selling Amid Market Concerns ADMA Biologics, a key player in the biopharmaceutical industry, is currently navigating a turbulent trading landscape, as evidenced by…
ADMA Biologics Advances in Production Efficiency with FDA Approval ADMA Biologics, a leader in the development of specialty biologics for the treatment of immune deficiencies, achieves a significant m…
ADMA Biologics Secures FDA Approval for Production Process Enhancement ADMA Biologics, a prominent player in the biopharmaceutical industry, recently achieves a significant milestone by receiving appr…
Adma Biologics and the Challenges of Specialty Pharmaceuticals In the rapidly evolving field of specialty pharmaceuticals, companies face a myriad of challenges that can significantly impact their ope…
Adma Biologics Inc. Navigates the Specialty Pharma Landscape Amid Market Challenges Adma Biologics Inc. operates in a challenging environment marked by financial instability and competitive pressures,…
ADMA Biologics Faces Scrutiny Following Auditor Resignation ADMA Biologics, Inc. is currently under investigation by Kirby McInerney LLP for potential violations of federal securities laws and other u…
ADMA Biologics Faces Legal Scrutiny Following Auditor Resignation ADMA Biologics, Inc. is currently under investigation by multiple law firms for potential violations of federal securities laws follow…